A Novel Immune Prognostic Index for Stratification of High-risk Patients with Early Breast Cancer

Overview

Journal Sci Rep

Specialty Science

Date 2021 Jan 9

PMID 33420250

Citations 5

Authors

Hannah Lee

Mi Jeong Kwon

Beom-Mo Koo

Hee Geon Park

Jinil Han

Young Kee Shin

Affiliations

Soon will be listed here.

Abstract

The prognostic value of current multigene assays for breast cancer is limited to hormone receptor-positive, human epidermal growth factor receptor 2-negative early breast cancer. Despite the prognostic significance of immune response-related genes in breast cancer, immune gene signatures have not been incorporated into most multigene assays. Here, using public gene expression microarray datasets, we classified breast cancer patients into three risk groups according to clinical risk and proliferation risk. We then developed the immune prognostic index based on expression of five immune response-related genes (TRAT1, IL2RB, CTLA4, IGHM and IL21R) and lymph node status to predict the risk of recurrence in the clinical and proliferation high-risk (CPH) group. The 10-year probability of disease-free survival (DFS) or distant metastasis-free survival (DMFS) of patients classified as high risk according to the immune prognostic index was significantly lower than those of patients classified as intermediate or low risk. Multivariate analysis revealed that the index is an independent prognostic factor for DFS or DMFS. Moreover, the C-index revealed that it is superior to clinicopathological variables for predicting prognosis. Its prognostic significance was also validated in independent datasets. The immune prognostic index identified low-risk patients among patients classified as CPH, regardless of the molecular subtype of breast cancer, and may overcome the limitations of current multigene assays.

Citing Articles

Minimally invasive determination of pancreatic ductal adenocarcinoma (PDAC) subtype by means of circulating cell-free RNA.

Metzenmacher M, Zaun G, Trajkovic-Arsic M, Cheung P, Reissig T, Schurmann H Mol Oncol. 2024; 19(2):357-376.

PMID: 39478658 PMC: 11792997. DOI: 10.1002/1878-0261.13747.

Differential molecular characterization of human papillomavirus-associated oropharyngeal squamous cell carcinoma and its prognostic value.

Wang H, Zhang Q, Zheng Z, Xin Y, Jiang X J Cell Mol Med. 2024; 28(19):e70073.

PMID: 39397259 PMC: 11471427. DOI: 10.1111/jcmm.70073.

Interleukine-2 serum level in breast cancer patients.

Harjianti T, Fachruddin A, Minhajat R, Saleh S, Bayu D Caspian J Intern Med. 2023; 14(3):479-484.

PMID: 37520880 PMC: 10379784. DOI: 10.22088/cjim.14.3.479.

Integrating single-cell and bulk RNA sequencing to develop a cancer-associated fibroblast-related signature for immune infiltration prediction and prognosis in lung adenocarcinoma.

Huang X, Xiao H, Shi Y, Ben S J Thorac Dis. 2023; 15(3):1406-1425.

PMID: 37065583 PMC: 10089835. DOI: 10.21037/jtd-23-238.

TRAT1 overexpression delays cancer progression and is associated with immune infiltration in lung adenocarcinoma.

Xiao X, Guo Q, Tong S, Wu C, Chen J, Ding Y Front Oncol. 2022; 12:960866.

PMID: 36276113 PMC: 9582843. DOI: 10.3389/fonc.2022.960866.

References

Huang D, Sherman B, Lempicki R . Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc. 2009; 4(1):44-57. DOI: 10.1038/nprot.2008.211. View

Yang B, Chou J, Tao Y, Wu D, Wu X, Li X . An assessment of prognostic immunity markers in breast cancer. NPJ Breast Cancer. 2018; 4:35. PMC: 6206135. DOI: 10.1038/s41523-018-0088-0. View

Teschendorff A, Caldas C . A robust classifier of high predictive value to identify good prognosis patients in ER-negative breast cancer. Breast Cancer Res. 2008; 10(4):R73. PMC: 2575547. DOI: 10.1186/bcr2138. View

Paik S, Tang G, Shak S, Kim C, Baker J, Kim W . Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. J Clin Oncol. 2006; 24(23):3726-34. DOI: 10.1200/JCO.2005.04.7985. View

Cardoso F, Vant Veer L, Bogaerts J, Slaets L, Viale G, Delaloge S . 70-Gene Signature as an Aid to Treatment Decisions in Early-Stage Breast Cancer. N Engl J Med. 2016; 375(8):717-29. DOI: 10.1056/NEJMoa1602253. View

Mao H, Zhang L, Yang Y, Zuo W, Bi Y, Gao W . New insights of CTLA-4 into its biological function in breast cancer. Curr Cancer Drug Targets. 2010; 10(7):728-36. DOI: 10.2174/156800910793605811. View

Parker J, Mullins M, Cheang M, Leung S, Voduc D, Vickery T . Supervised risk predictor of breast cancer based on intrinsic subtypes. J Clin Oncol. 2009; 27(8):1160-7. PMC: 2667820. DOI: 10.1200/JCO.2008.18.1370. View

Harris L, Ismaila N, McShane L, Andre F, Collyar D, Gonzalez-Angulo A . Use of Biomarkers to Guide Decisions on Adjuvant Systemic Therapy for Women With Early-Stage Invasive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol. 2016; 34(10):1134-50. PMC: 4933134. DOI: 10.1200/JCO.2015.65.2289. View

Yeong J, Lim J, Lee B, Li H, Chia N, Ong C . High Densities of Tumor-Associated Plasma Cells Predict Improved Prognosis in Triple Negative Breast Cancer. Front Immunol. 2018; 9:1209. PMC: 5988856. DOI: 10.3389/fimmu.2018.01209. View

10.

Oh E, Choi Y, Park T, Lee S, Nam S, Shin Y . A prognostic model for lymph node-negative breast cancer patients based on the integration of proliferation and immunity. Breast Cancer Res Treat. 2011; 132(2):499-509. DOI: 10.1007/s10549-011-1626-8. View

11.

Bogunovic D, ONeill D, Belitskaya-Levy I, Vacic V, Yu Y, Adams S . Immune profile and mitotic index of metastatic melanoma lesions enhance clinical staging in predicting patient survival. Proc Natl Acad Sci U S A. 2009; 106(48):20429-34. PMC: 2787158. DOI: 10.1073/pnas.0905139106. View

12.

Jounaidi Y, Cotten J, Miller K, Forman S . Tethering IL2 to Its Receptor IL2Rβ Enhances Antitumor Activity and Expansion of Natural Killer NK92 Cells. Cancer Res. 2017; 77(21):5938-5951. PMC: 6204197. DOI: 10.1158/0008-5472.CAN-17-1007. View

13.

Teschendorff A, Miremadi A, Pinder S, Ellis I, Caldas C . An immune response gene expression module identifies a good prognosis subtype in estrogen receptor negative breast cancer. Genome Biol. 2007; 8(8):R157. PMC: 2374988. DOI: 10.1186/gb-2007-8-8-r157. View

14.

Cheang M, Voduc D, Bajdik C, Leung S, McKinney S, Chia S . Basal-like breast cancer defined by five biomarkers has superior prognostic value than triple-negative phenotype. Clin Cancer Res. 2008; 14(5):1368-76. DOI: 10.1158/1078-0432.CCR-07-1658. View

15.

Partridge A, Carey L . Unmet Needs in Clinical Research in Breast Cancer: Where Do We Need to Go?. Clin Cancer Res. 2017; 23(11):2611-2616. PMC: 5512575. DOI: 10.1158/1078-0432.CCR-16-2633. View

16.

Schmidt M, Bohm D, von Torne C, Steiner E, Puhl A, Pilch H . The humoral immune system has a key prognostic impact in node-negative breast cancer. Cancer Res. 2008; 68(13):5405-13. DOI: 10.1158/0008-5472.CAN-07-5206. View

17.

Tiberi D, Masucci L, Shedid D, Roy I, Vu T, Patocskai E . Limitations of Personalized Medicine and Gene Assays for Breast Cancer. Cureus. 2017; 9(3):e1100. PMC: 5393908. DOI: 10.7759/cureus.1100. View

18.

Leek J, Johnson W, Parker H, Jaffe A, Storey J . The sva package for removing batch effects and other unwanted variation in high-throughput experiments. Bioinformatics. 2012; 28(6):882-3. PMC: 3307112. DOI: 10.1093/bioinformatics/bts034. View

19.

Paik S, Shak S, Tang G, Kim C, Baker J, Cronin M . A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med. 2004; 351(27):2817-26. DOI: 10.1056/NEJMoa041588. View

20.

Wolf D, Lenburg M, Yau C, Boudreau A, J van t Veer L . Gene co-expression modules as clinically relevant hallmarks of breast cancer diversity. PLoS One. 2014; 9(2):e88309. PMC: 3917875. DOI: 10.1371/journal.pone.0088309. View